<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BRAF is an oncogene encoding a serine-threonine protein kinase involved in the MAPK signalling cascade </plain></SENT>
<SENT sid="1" pm="."><plain>BRAF acts as direct effector of <z:mp ids='MP_0011356'>RAS</z:mp> and through the activation of MEK, promotes <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumour growth</z:e> and survival </plain></SENT>
<SENT sid="2" pm="."><plain>Approximately, 8% of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> carry a BRAF mutation </plain></SENT>
<SENT sid="3" pm="."><plain>However, the prevalence of this mutation varies significantly across different <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types </plain></SENT>
<SENT sid="4" pm="."><plain>There has been increasing interest in the specific role of BRAF mutations in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> growth and progression over the last few years, especially since the clinical introduction of therapeutic BRAF inhibitors </plain></SENT>
<SENT sid="5" pm="."><plain>In this paper we review the published literature on the role of BRAF mutations in <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, focusing on similarities and differences of BRAF mutations with respect to frequency, demographics, risk factors, mutation-associated clinico-pathologic and molecular features and clinical implications between these two diseases </plain></SENT>
</text></document>